The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Colazide     disodium (3E)-3-[[4-(2...

Synonyms: Balzide, Giazo, balsalazine, AC1NUNZE, CHEMBL1200760, ...
This record was replaced with 5362070.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of BALSALAZIDE


High impact information on BALSALAZIDE


Chemical compound and disease context of BALSALAZIDE


Anatomical context of BALSALAZIDE


Associations of BALSALAZIDE with other chemical compounds


Analytical, diagnostic and therapeutic context of BALSALAZIDE


  1. Inflammation's role in rectal cancer following prostate radiotherapy, and emerging evidence for a protective role for balsalazide. Jahraus, C.D., Rubin, D.T., Scherl, E.J., Bettenhausen, D. Gastroenterology (2005) [Pubmed]
  2. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Kruis, W., Schreiber, S., Theuer, D., Brandes, J.W., Schütz, E., Howaldt, S., Krakamp, B., Hämling, J., Mönnikes, H., Koop, I., Stolte, M., Pallant, D., Ewald, U. Gut (2001) [Pubmed]
  3. Prevention of acute radiation-induced proctosigmoiditis by balsalazide: a randomized, double-blind, placebo controlled trial in prostate cancer patients. Jahraus, C.D., Bettenhausen, D., Malik, U., Sellitti, M., St Clair, W.H. Int. J. Radiat. Oncol. Biol. Phys. (2005) [Pubmed]
  4. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Pruitt, R., Hanson, J., Safdi, M., Wruble, L., Hardi, R., Johanson, J., Koval, G., Riff, D., Winston, B., Cross, A., Doty, P., Johnson, L.K. Am. J. Gastroenterol. (2002) [Pubmed]
  5. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group. Green, J.R., Gibson, J.A., Kerr, G.D., Swarbrick, E.T., Lobo, A.J., Holdsworth, C.D., Crowe, J.P., Schofield, K.J., Taylor, M.D. Aliment. Pharmacol. Ther. (1998) [Pubmed]
  6. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Nugent, S.G., Kumar, D., Rampton, D.S., Evans, D.F. Gut (2001) [Pubmed]
  7. How important is onset of action in ulcerative colitis therapy? Masson, S., Nylander, D., Mansfield, J.C. Drugs (2005) [Pubmed]
  8. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Mansfield, J.C., Giaffer, M.H., Cann, P.A., McKenna, D., Thornton, P.C., Holdsworth, C.D. Aliment. Pharmacol. Ther. (2002) [Pubmed]
  9. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease. Prakash, A., Markham, A. Drugs (1999) [Pubmed]
  10. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Sandborn, W.J. Reviews in gastroenterological disorders. (2006) [Pubmed]
  11. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Chan, R.P., Pope, D.J., Gilbert, A.P., Sacra, P.J., Baron, J.H., Lennard-Jones, J.E. Dig. Dis. Sci. (1983) [Pubmed]
  12. Thyrotoxicosis co-existing with ulcerative colitis. Pai, S., Mehta, R., Rao, G. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology. (2005) [Pubmed]
  13. Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies. Simmonds, N.J., Millar, A.D., Blake, D.R., Rampton, D.S. Aliment. Pharmacol. Ther. (1999) [Pubmed]
  14. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Sandborn, W.J., Hanauer, S.B., Buch, A. Aliment. Pharmacol. Ther. (2004) [Pubmed]
  15. VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases. Chapman, T.M., Plosker, G.L., Figgitt, D.P. Drugs (2006) [Pubmed]
WikiGenes - Universities